Статья

Dihydromyricetin alleviates Escherichia coli lipopolysaccharide-induced hepatic injury in chickens by inhibiting the NLRP3 inflammasome

Chenxi ShiBasic Veterinary Department, College of Veterinary Medicine, Northeast Agricultural University, Harbin, ChinaJiaqi WangBasic Veterinary Department, College of Veterinary Medicine, Northeast Agricultural University, Harbin, ChinaRuichen ZhangBasic Veterinary Department, College of Veterinary Medicine, Northeast Agricultural University, Harbin, ChinaMuhammad IshfaqBasic Veterinary Department, College of Veterinary Medicine, Northeast Agricultural University, Harbin, ChinaYing LiBasic Veterinary Department, College of Veterinary Medicine, Northeast Agricultural University, Harbin, ChinaRuihui ZhangBasic Veterinary Department, College of Veterinary Medicine, Northeast Agricultural University, Harbin, ChinaChuanbiao SiBasic Veterinary Department, College of Veterinary Medicine, Northeast Agricultural University, Harbin, ChinaRui LiBasic Veterinary Department, College of Veterinary Medicine, Northeast Agricultural University, Harbin, ChinaChangwen LiLaboratory Animal Base, Harbin Veterinary Research Institute of Chinese Academy of Agricultural Sciences, Harbin, ChinaFangping LiuBasic Veterinary Department, College of Veterinary Medicine, Northeast Agricultural University, Harbin, China. [email protected]

2022en

ABI

Аннотация

Abstract Dihydromyricetin (DHM), a flavonoid in vine tea, has many pharmacological activities, including anti-inflammatory and antibacterial effects. Lipopolysaccharide is the key inducer of inflammation in avian pathogenic Escherichia coli ( E. coli ) infection; however, the effect of DHM on E. coli lipopolysaccharide-induced hepatic injury remains unknown. The present study aimed to explore the role of the NLRP3 inflammasome in hepatic injury and the possible protective mechanisms of DHM against hepatic injury in chickens. The results showed that when chickens were administered lipopolysaccharide, liver damage was observed, accompanied by increased levels of serum transaminases and direct bilirubin. Additionally, hepatic expression levels of NLRP3 and caspase-1 p20, the subunit of caspase-1 that is cleaved after NLRP3 activation, significantly increased in liver injury. We found that treatment with MCC950, a specific NLRP3 inhibitor, significantly decreased serum transaminase activities, direct bilirubin content, and hepatic NLRP3 and caspase-1 p20 expression levels. DHM significantly reduced serum transaminase activities and direct bilirubin content and ameliorated histopathological and ultrastructural changes in the liver. DHM decreased hepatic levels of H 2 O 2 and malondialdehyde and increased the activities of superoxide dismutase and glutathione peroxidase. Furthermore, DHM significantly decreased the expression levels of NLRP3, pro-caspase-1 and caspase-1 p20. Moreover, DHM reduced serum lactate dehydrogenase, IL-1β and IL-18 levels and repressed hepatic IL-1β, IL-18 and gasdermin A expression. The results demonstrated that the NLRP3 inflammasome was involved in the mechanism of lipopolysaccharide-induced hepatic injury. Furthermore, DHM could inhibit NLRP3 inflammasome activation and subsequent pyroptosis, eventually ameliorating E. coli lipopolysaccharide-induced liver injury.

Перевод пока недоступен

Идентификаторы

DOI: 10.1186/s13567-022-01024-1

Цитирования и источники

Цитирований: 2Использованных источников: 0

Показатели — AkademScholar